View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
September 11, 2019updated 12 Jul 2022 12:23pm

AMRA partners with Micron to expand reach of trials in Japan

Sweden-based AMRA Medical will support its pharmaceutical and research customers in carrying out clinical trials in Japan after partnering with imaging contract research organisation (CRO) Micron.

Sweden-based AMRA Medical Inc” target=”_blank”>AMRA Medical will support its pharmaceutical and research customers in carrying out clinical trials in Japan after partnering with imaging contract research organisation (CRO) Micron .

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

Under the partnership, AMRA ’s MRI Body Composition Profiling and expertise in metabolic diseases, musculoskeletal conditions and muscle wasting will be combined with Micron ’s existing reach in Japan’s imaging research markets.

AMRA CEO Eric Converse said: “We are very happy to have Micron as a partner for the second largest medical market. A local partner in the sophisticated Japanese market is necessary and will mean better service to domestic clients.”

Micron is said to have the biggest medical imaging analysis team in Japan. Its logistical organisation and expertise will be used to support the launch of AMRA ’s technology in Japanese clinical trials.

Micron president Michita Sato said: “Micron has a corporate mission that Micron is committed to human health and medical progression by supporting research activities in the medical field through utilising imaging technologies.

“To introduce AMRA ‘s technology into Japan definitely matches this mission and we believe it will bring an innovative step for the researches of pharmaceuticals and academics. AMRA has a unique capability that uses AI with high precision and in 3D quantify the whole muscles and fat in rapid MRI scans.”

AMRA Global Business Development and Marketing senior vice-president Rosemary Shull said: “Japanese pharmaceutical companies and academic researchers show great interest in AMRA ‘s digital health solutions and with this partnership, we can expect increased business and strengthen our relationships in Japan”

Founded in 2010, AMRA produces muscle and fat biomarkers and deliver disease insights from a single, rapid, whole-body MRI.

Related Companies

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena